NDAINHALATIONGAS
Approved
Jul 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
4/8 — Partial
CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. Approved for vocal cord dysfunction, respiratory papillomatosis, human papillomavirus infection and 11 more indications. First approved in 2013.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARBON DIOXIDE, USP is an inhaled gas therapeutic agent approved as a radiographic contrast medium with a mechanism of X-ray contrast activity. The product is indicated for a diverse range of conditions including vocal cord dysfunction, respiratory papillomatosis, migraine, burns, actinic keratosis, and acute respiratory distress syndrome, among others. Its multi-indication profile suggests a platform utility across respiratory, dermatologic, and neurologic indications.
Peak
Product is at peak commercial maturity since 2013 approval; team size and growth trajectory depend on indication penetration and managed care access.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.